Document is current
Any future updates will be listed below
-
Authors
Van Egroo, Maxime
Beckers, Elise
Ashton, Nicholas J.
Blennow, Kaj
Zetterberg, Henrik
Jacobs, Heidi I. L.
-
Funding
Funding for this research was provided by:
BrightFocus Foundation (A20211016F)
European Union’s Marie Skłodowska-Curie Actions (101109451-ADEEPSLEEP)
Maastricht University – ULiège Imaging Valley
Swedish Research Council (#2017-00915)
Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397)
Alzheimer’s Drug Discovery Foundation (#RDAPB-201809-2016615)
Alzheimer’s Drug Discovery Foundation (#201809-2016862)
Swedish Alzheimer Foundation (#AF-930351, #AF-939721 and #AF-968270)
Hjärnfonden (#FO2017-0243 and #ALZ2022-0006)
Hjärnfonden (#FO2022-0270)
Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240)
European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236)
National Institutes of Health (#1R01AG068398-01)
National Institutes of Health (R01AG062559, R01AG06806, R01AG082006, and R21AG074220)
Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495)
European Union’s Horizon Europe research and innovation programme (101053962)
Swedish State Support for Clinical Research (#ALFGBG-71320)
AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C)
Bluefield Project
Cure Alzheimer’s Fund
Olav Thon Foundation
Erling-Persson Family Foundation
Stiftelsen för Gamla Tjänarinnor
European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant (860197 (MIRIADE))
European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694)
National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre
UK Dementia Research Institute at UCL (UKDRI-1003)
Alzheimer Nederland (#WE.03-2019-02)
Alzheimer’s Association (AARG-22-920434)
Centre for Integrative Neuroscience, Maastricht University, the Netherlands
- License Information
-
More Information
Article History
Received: 22 April 2024
Accepted: 18 December 2024
First Online: 30 December 2024
Declarations
:
: This study was approved by the local medical ethics committee of the Faculty of Health, Medicine and Life Sciences at Maastricht University, Maastricht, the Netherlands (#METC183002), and was conducted in accordance with the principles of the Declaration of Helsinki. All participants provided written informed consent prior to participation and received a monetary compensation.
: Not applicable.
: N.J.A. has given lectures in symposia sponsored by Eli Lily, and is an associate editor at Alzheimer’s Research & Therapy. K.B. has served as a consultant at advisory boards or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work), and is member of the editorial board at Alzheimer’s Research & Therapy. H.Z. has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). H.I.L.J. is chair of the Neuromodulatory Subcortical Systems Professional Interest Area of ISTAART and advisory board member of ISTAART. All other authors report no conflict of interest.
